title: Gonadotropin-releasing hormone antagonist use in controlled ovarian stimulation and intrauterine insemination cycles in women with polycystic ovary syndrome.
abstract: OBJECTIVE
  To observe the effects of ganirelix on controlled ovarian stimulation and intrauterine insemination (COS/IUI) cycles in women with polycystic ovary syndrome (PCOS).
  
  
  METHODS
  Prospective, randomized, controlled clinical study.
  
  
  METHODS
  An academic clinical research center.
  
  
  METHODS
  Women with PCOS and anovulatory infertility undergoing COS/IUI.
  
  
  METHODS
  Recombinant FSH therapy was started on day 3. In women assigned to the control group (n = 47), treatment was continued up to the day of hCG administration. In patients assigned to receive GnRH antagonist (n = 42), ganirelix was added when the leading follicle was > or =14 mm.
  
  
  METHODS
  Pregnancy rates, serum E(2), P, and LH levels, and follicle numbers at hCG day, prevalence of premature luteinization, and cost of stimulation.
  
  
  RESULTS
  Serum E(2), P, and LH levels were significantly lower in the ganirelix group. Although premature luteinization and cycle cancellation was encountered less in the ganirelix group, the pregnancy rates per cycle were similar (15.4% vs. 10.7%). Patients would pay 6,153 dollars more for each pregnancy when using ganirelix.
  
  
  CONCLUSIONS
  Gonadotropin-releasing hormone antagonist resulted in more monofollicular development, less premature luteinization, and less cycle cancellation in IUI cycles of patients with PCOS; however, the cost of stimulation increased without an improvement in pregnancy rates.
authors.affiliation: Department of Obstetrics and Gynecology, School of Medicine, Mersin University, Mersin, Turkey. devrimertunc@hotmail.com
authors.forename: Devrim
authors.initials: D
authors.lastname: Ertunc
authors.forename: Ekrem C
authors.initials: EC
authors.lastname: Tok
authors.forename: Aysun
authors.initials: A
authors.lastname: Savas
authors.forename: Ilay
authors.initials: I
authors.lastname: Ozturk
authors.forename: Saffet
authors.initials: S
authors.lastname: Dilek
mesh_terms: D000328:Adult; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives* / Q000037:antagonists & inhibitors* / Q000097:blood / Q000494:pharmacology / Q000627:therapeutic use; D006727:Hormone Antagonists / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D007247:Infertility, Female / Q000097:blood / Q000188:drug therapy / Q000209:etiology; D007317:Insemination, Artificial, Homologous / Q000379:methods*; D008297:Male; D010062:Ovulation Induction / Q000379:methods*; D011085:Polycystic Ovary Syndrome / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D011247:Pregnancy; D011446:Prospective Studies; D055815:Young Adult
chemical_list: D006727:Hormone Antagonists; D007987:Gonadotropin-Releasing Hormone; C061018:ganirelix